Quarterly report pursuant to Section 13 or 15(d)

Related Party Transactions (Details Narrative)

v3.20.2
Related Party Transactions (Details Narrative) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Jan. 31, 2020
Sep. 30, 2020
Sep. 30, 2020
Dec. 31, 2019
 [1]
License fee   $ 47 $ 126  
Related party receivable   $ 2 $ 2 $ 18
Shared Space Agreement [Member]        
Shared space agreement, description The Company entered into a license agreement (the "Shared Space Agreement") with Orchestra BioMed, Inc., a greater than 5% holder of the Company's common stock and entity in which David Hochman, the Chairman of the Company's board of directors, serves as the Chairman of the board of directors and Chief Executive Officer, and Darren Sherman, a member of the Company's board of directors, serves as a director and as President and Chief Operating Officer. As of September 30, 2020, the Company has a related party receivable in the amount of $2 in relation to the Shared Space Agreement. During the three and nine months ended September 30, 2020, the Company recorded license fee of $47 and $126, respectively, in relation to the Shared Space Agreement.      
Percentage of holder of common stock 5.00%      
Expire date     Sep. 30, 2024  
Shared Space Agreement [Member] | Minimum [Member]        
License fee     $ 162  
Shared Space Agreement [Member] | Maximum [Member]        
License fee     $ 198  
[1] Derived from audited consolidated financial statements